AbCellera Biologics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.10.22	AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022 (Businesswire)
21.09.22	AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic (Businesswire)
09.08.22	AbCellera Reports Q2 2022 Business Results (Businesswire)
03.08.22	AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients (Businesswire)
27.07.22	Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies (Businesswire)
12.07.22	AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022 (Businesswire)
29.06.22	Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options (Businesswire)
10.05.22	AbCellera Reports Q1 2022 Business Results (Businesswire)
03.05.22	AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration (Businesswire)
26.04.22	AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022 (Businesswire)
12.04.22	AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022 (Businesswire)
08.04.22	AbCellera Presents Data on T Cell Engager Platform at AACR 2022 (Businesswire)
24.02.22	AbCellera Reports Full Year 2021 Business Results (Businesswire)
23.02.22	AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools (Businesswire)
11.02.22	AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022 (Businesswire)
11.02.22	AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19 (Businesswire)
11.02.22	Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments (Businesswire)
17.09.21	Pre-market Movers: CRVS, ABCL, BGNE, IPHA, IRNT… (RTTNews)
23.06.21	Pre-market Movers: ACST, TENX, GMTX, EYES… (RTTNews)
22.06.21	AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada (Businesswire)
10.06.21	AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares (Businesswire)
13.05.21	AbCellera Reports Q1 2021 Business Results (Businesswire)
11.05.21	AbCellera to Present Virtually at Berenberg Conference on May 18, 2021 (Businesswire)
06.05.21	AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy (Businesswire)
04.05.21	New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials (Businesswire)
29.04.21	AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals (Businesswire)
21.04.21	AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021 (Businesswire)
14.04.21	AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration (Businesswire)
05.04.21	Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19 (Businesswire)
10.03.21	AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19 (Businesswire)
05.03.21	EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients (Businesswire)
17.02.21	AbCellera to Present at the SVB Leerink Global Healthcare Conference (Businesswire)
11.02.21	AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer (Businesswire)
10.02.21	AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19 (Businesswire)
03.02.21	AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call (Businesswire)
27.01.21	AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19 (Businesswire)
26.01.21	AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70% (Businesswire)
19.01.21	AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology (Businesswire)
21.12.20	AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	527.00	2.33 %	K V
Holcim	95.34	1.21 %	K V
UBS Group	30.42	0.86 %	K V
Roche Hldg G	289.00	0.45 %	K V
Swiss Re	141.65	0.35 %	K V
Givaudan	3’850.00	-1.48 %	K V
Lonza Grp	603.80	-1.50 %	K V
Alcon	82.30	-1.53 %	K V
Geberit	508.00	-1.74 %	K V
Part Grp Hldg	1’386.00	-2.26 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu AbCellera Biologics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten